| Revenue growth | 8% Y-o-Y |
|---|---|
| Margins | EBITDA margin at 2.30% (+159 BPS Y-o-Y); gelatine capsules delivering healthy margins. |
| Demand visibility | Firm demand in capsules; erratic US HPMC environment. |
| Management confidence | Confident in sustained profitability for capsules; improved visibility for Q2FY27. |
Growth
Revenue grew 8% Y-o-Y to ₹48.71 Cr; PAT stood at a loss of ₹5.74 Cr. EBITDA rose 251% Y-o-Y.
Outlook
Converting two HPMC lines to gelatine; expecting first backward-integrated prednisolone batch by September 2026. PLI incentive of ~₹67 Cr over 6 years.
Risks
US HPMC demand remains erratic; geopolitical uncertainty and currency fluctuations impacting African export volumes via merchant exporters.
Last quarter's promises, checked
Delivered
- Guided Q4FY26 API sales start → Delivered Q4FY26 commencement (= BEAT)
- Guided HPMC line ready for qualification → Delivered ready for double zero (= BEAT)
Partly delivered
- Guided WHO GMP audit Q2FY27 → Delivered application initiated/audit expected (= PARTIAL)
- Guided Prednisolone commercial scale-up Q2/Q3 → Delivered synthesis at gram-scale (= PARTIAL)
Missed
- Guided FY27 HPMC revenue ₹20 Cr → Delivered Q1FY27 erratic demand (= MISS)
- Guided FY27 API revenue ₹70 Cr → Delivered Q1FY27 mixed picture/lower run-rate (= MISS)
Investor Presentation filed with BSE, NSE: NATCAPSUQ. Summary written with AI assistance from the document.
Natural Capsules Ltd: key numbers
- Share price
- ₹169.52
- Market cap
- ₹176.5 Cr
- Revenue (annual)
- ₹187.2 Cr
- Net profit (annual)
- ₹-24.66 Cr
- P/E (TTM)
- -8.2×Sector 50.4×
- Promoter holding
- 50.92%-0.12% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natural Capsules Ltd
All →Natural Capsules Annual General Meeting
Natural Capsules Ltd dispatched a corrigendum to its upcoming EGM notice, revising the issue price and quantity for the proposed preferential allotment of shares and warrants.
Natural Capsules Fund Raise of ₹10.01 Cr
Natural Capsules Limited approved a revised preferential issue of 1,12,500 equity shares and 4,50,000 convertible warrants. The total aggregate fund raise is valued at Rs. 10.01 Crore.
- Value
- ₹10.01 Cr
Natural Capsules Q1 FY27 Results: Net Loss of ₹5.7 Cr, Loss Widens
Natural Capsules Ltd reported revenue from operations of ₹48.7 Cr (+7.7% YoY) and a net loss of ₹5.7 Cr for Q1 FY27.
- Key figure
- Net loss ₹5.7 Cr
Natural Capsules Earnings Call: Key Takeaways
Natural Capsules Ltd reported Q4 FY26 revenue of ₹58.45cr (up 55% QoQ). Full-year FY26 revenue grew 11% to ₹187.20cr, though the company posted a net loss of ₹24.66cr.
Natural Capsules Earnings Call: Key Takeaways
Natural Capsules reports Q4FY26 revenue of ₹58.45 Cr (+30% Y-o-Y) while facing a PAT loss of ₹4.98 Cr. Strategy focuses on steroidal API scaling and HPMC capsule expansion.
Natural Capsules Q4 FY26 Results: Net Loss of ₹5 Cr
Natural Capsules Ltd reported revenue from operations of ₹58.5 Cr (+30.0% YoY) and a net loss of ₹5 Cr for Q4 FY26.
- Key figure
- Net loss ₹5 Cr